Launch of international pilot programme on inspection of manufacturers of sterile medicines

On 17 December 2019 the EMA updated the international collaboration on GMP inspections.

In December 2019, EMA and its European and international partners launched a pilot programme to share information on GMP inspections of manufacturers of sterile medicines located outside the participating countries and to organise joint inspections of manufacturing sites of common interest.

The products in scope include sterile medicines for human use of chemical origin and certain therapeutic biotechnology-derived products, such as monoclonal antibodies and recombinant proteins.

Vaccines, cell and gene therapies and plasma-derived pharmaceuticals are currently out of the scope of this pilot.

Read the pdf
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /